Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Hemangioma 8 Hemangioma, Capillary 7 Melanoma 6 Breast Neoplasms 5 Carcinoma, Hepatocellular 4 Sarcoma 3 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Multiple Myeloma 3 Hypertension, Portal 3 Hemangiosarcoma 3 Fallopian Tube Neoplasms 3 Urinary Bladder Neoplasms 2 Sarcoma, Kaposi 2 Ovarian Neoplasms 2 Hemangioma, Cavernous, Central Nervous System 2 Colorectal Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Carcinoma, Non-Small-Cell Lung 2 von Hippel-Lindau Disease 1 Uterine Cervical Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Ulcer 1 Tuberous Sclerosis 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Spinal Cord Neoplasms 1 Smoldering Multiple Myeloma 1 Skin Neoplasms 1

Interventions

Everolimus 18 Sirolimus 15 Cannabidiol 5 radiprodil 3 ganaxolone 3 Vigabatrin 3 Activator Appliances 3 Melatonin 2 exemestane 1 dactolisib 1 carbon-11 acetate 1 Surveys and Questionnaires 1 Simvastatin 1 Sertraline 1 Selective Serotonin Reuptake Inhibitors 1 Propranolol 1 Itraconazole 1 Injections 1 Fluid Therapy 1 Doxycycline 1 Curcumin 1 Carbamazepine 1 Calcitriol 1 Aspirin 1 Anticonvulsants 1 Actigraphy 1 Acceptance and Commitment Therapy 1 2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl)pyridine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Tuberous Sclerosis × Propranolol × Clear all

NCT02104011 2026-05-19

STBETA

University Hospital, Bordeaux

Phase 2 Completed

Tuberous Sclerosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡